Heart failure (HF) is a debilitating and life-threatening condition, with 5-year survival rate lower than breast or prostate cancer. It is the leading cause of hospital admission in over 65s, and these admissions are projected to rise by more than 50% over the next 25 years. Transthoracic echocardiography (TTE) is the first-line step in diagnosis in acute and chronic HF and provides immediate information on chamber volumes, ventricular systolic and diastolic function, wall thickness, valve function and the presence of pericardial effusion, while contributing to information on aetiology. Dilated cardiomyopathy (DCM) is the third most common cause of HF and is the most common cardiomyopathy. It is defined by the presence of left ventricular dilatation and left ventricular systolic dysfunction in the absence of abnormal loading conditions (hypertension and valve disease) or coronary artery disease sufficient to cause global systolic impairment. This document provides a practical approach to diagnosis and assessment of dilated cardiomyopathy that is aimed at the practising sonographer.
Introduction
1.1. The BSE Education Committee has previously published a minimum dataset for a standard adult transthoracic echocardiogram (TTE). These are published online in Echo Research and Practice (1) . This document specifically states that the minimum dataset is usually only sufficient when the echocardiographic study is entirely normal. The aim of the Education Committee is to publish a series of appendices to cover specific pathologies to support this minimum dataset. This final document completes the cardiomyopathy series (hypertrophic (2) , restrictive (3), ARVC (4) and dilated cardiomyopathies).
The intended benefits of such supplementary recommendations are to:
• Support cardiologists and echocardiographers to develop local protocols and quality control programmes for adult transthoracic study.
• Promote quality by defining a set of descriptive terms and measurements, in conjunction with a systematic approach to perform and report a study in specific disease states.
• Facilitate the accurate comparison of serial echocardiograms performed in patients at the same or different sites.
1.3. The views and measurements are focussed upon dilated cardiomyopathy and are supplementary to those outlined in the TTE minimum dataset. This document gives recommendations for the image and analysis dataset required in patients either being assessed for or with a known diagnosis of dilated cardiomyopathy.
1.4. When the condition or acoustic windows of the patient prevent the acquisition of one or more components of the supplementary dataset or when measurements result in misleading information (e.g. offaxis measurements) this should be stated.
1.5. This document is a guideline for echocardiography in dilated cardiomyopathy and will be updated in accordance with changes directed by publications or changes in practice.
Dilated cardiomyopathy
2.1. Dilated cardiomyopathy (DCM) is a progressive disease of the heart muscle. It is characterised by chamber enlargement and contractile dysfunction of the left ventricle in the absence of chronic pressure and/or volume overload. Although not essential for diagnosis, the right ventricle may similarly be affected. Dilated cardiomyopathy is the third most common cause of heart failure and is the commonest type of cardiomyopathy (5) . The phenotype of ventricular dilatation and abnormal contractile dysfunction can be the result of a range of pathological conditions such as infection, toxins or autoimmune disease. However, in 50% of cases, the aetiology remains unknown and is termed 'idiopathic DCM'. It is recognised that between 20% and 35% of idiopathic cases may have a family history suggesting an inherited gene defect (6).
Echocardiography is the first-line imaging test
in the assessment of patients with DCM. It provides pivotal information not only for diagnosis, risk stratification and guiding treatment, but also plays a key role in screening family members. This document provides recommendations for the acquisition of images and collection of a dataset to be analysed during echocardiography in the assessment of patients with suspected or known DCM.
2.3. In this document, the parameters used for diagnosis and risk stratification are set out systematically (Table 1) . Appendix 1 provides additional information on some of these parameters, Appendix 2 describes the echocardiographic features that help to differentiate the commonly encountered conditions presenting as DCM and finally a list of useful references for further reading.
2.4. The diagnostic criteria for DCM require exclusion of chronic pressure overload (such as hypertension and left ventricular outflow obstruction), chronic volume overload states (intra-cardiac shunts and valvular regurgitation) and ischaemic heart disease. LV dP/dt max = 32 mmHg/time (s) dp/dt is a measure of global LV contractility
Normal value: 1000-1200 mmHg/s dp/dt <600 mmHg/s is an adverse prognostic marker (17) dysynchrony is important to identify patients who may benefit from cardiac resynchronisation therapy (CRT). Several echocardiographic parameters have been used to assess mechanical dysynchrony in small subsets of patients; however, the wider role of echocardiography in selecting patients for CRT is still debated. Currently, the role of echo is limited to patients with borderline QRS duration (120-149 ms) in which the presence of inter or intraventricular dysynchrony may provide additional information (22) . Assessment of dysynchrony is therefore not part of the routine dataset for patients with DCM and should be used as an option in selected cases only. e. Stress echo and contractile reserve: Assessment of contractile reserve by low-dose dobutamine stress echocardiography may refine prognosis in patients with DCM and may be used when cardiopulmonary exercise stress testing is not available or in patients who are unable to exercise. An increase in LV EF from rest to peak stress by ≥5% or a percentage change from baseline of ≥20% indicates the presence of contractile reserve. Its absence is an adverse prognostic marker (23 
Declaration of interest

